This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Objective To explore trends in prognosis and use of glucose-lowering drugs (GLD) in patients with diabetes and coronaryarterydisease (CAD). Information on GLD (dispended 6 months before or after coronary angiography) was collected from the Swedish Prescribed Drug Registry.
Deficits in health literacy are common in patients with coronaryarterydisease (CAD), and this is associated with increased morbidity and mortality. We searched electronic databases for studies published since 2010.
The PCI trend remained unchanged from 2007 to 2010 and then increased significantly (annual percentage change, 3.2%;P=0.02). Joinpoint regression and multivariable logistic regression analyses were performed to assess the annual percentage change in trends and predictors of the 30‐day mortality rate, respectively.
NEJM 2010. For more information: www.heartflow.com References 1. Arbab-Zadeh, Heart Int 2012. Yokota, et al. Neth Heart J 2018. Nakanishi, et al. J Nucl Cardiol 2016. Patel et al. 2021 ACC/AHA Chest Pain Guidelines. Turnaround time is defined as the time it takes from customer CCTA submission for HeartFlow to deliver back the FFRCT Analysis.
Previously, 80% of sudden cardiac arrest have been attributed to coronaryarterydisease. Among hospitalised patients, 30% were diagnosed with AMI, 27% with hypertension, 20% with ischaemic heart disease and 18% with heart failure as discharge diagnoses.
Methods CE-MARC 2, a three-arm parallel group trial, randomised patients with suspected stable cardiac chest pain and a Duke Clinical pretest likelihood of coronaryarterydisease between 10% and 90%. 12) Questionnaire and EuroQol-5 Dimension Questionnaire were recorded. QoL scores did not significantly differ across domains.
Self-reported adherence to cardiovascular medications in patients who have coronaryarterydisease is for the combination of aspirin, beta-blocker and a lipid-lowering agent in surveys.7 Long-Term Adherence to Evidence-Based Secondary Prevention Therapies in CoronaryArteryDisease. BMC Med2015;13(74).
This study aims to compare mortality rates within one year of STEMI patients among the public health insurance schemes of Thailand.MethodologyThis study is a single-center retrospective analysis of patients with STEMI treated with primary percutaneous coronary intervention (pPCI).
We aimed to examine the prevalence of VRFs and temporal trends in VRF burden among young patients presenting with IS.Methods:Data was prospectively collected by Get With the Guidelines-Stroke® hospitals participating in the Florida Stroke Registry between January 2010 and December 2022.
Subscribe now APOE4 & Cardiovascular Risk We now know that carriers of APOE4 typically have higher circulating APOB levels, but the question is how much this influences the risk of cardiovascular disease. 2010 Aug 5;3:53-64. Sci Transl Med. 2021 Mar 3;13(583):eaaz4564. doi: 10.1126/scitranslmed.aaz4564. Appl Clin Genet. 7 Ashiq, S.,
The patient was in his 50s with history of hypertension, diabetes, seizure disorder, and smoking, but no known coronaryarterydisease. In the graphic below you can see the proportion of coronary occlusions which were identified by the STEMI criteria subdivided by coronaryartery and presence of extended leads.
v As cardiovascular disease (CVD) continues to rise globally, vi the need for advanced diagnostic technologies like cardiac CT angiography (CCTA) becomes increasingly critical. CCTA offers a non-invasive, cost-effective, and highly sensitive method for diagnosing coronaryarterydisease (CAD), making it a valuable tool for clinicians.
The company reports this broadens the use of the novel bioadaptor platform technology beyond the treatment of coronaryarterydisease. Global and regional burden of death and disability from peripheral arterydisease: 21 world regions, 1990 to 2010. Glob Heart. 2014;9(1):145-158 e121.
I think especially with the recent changes in guidelines and the recommendation to use CT for screening of coronaryarterydisease, we expect to see this trend really impact the way CT is used in the future.” “The CT procedural mix is evolving, and cardiac CT is starting to account for a large proportion of that.
FAME study showed that at one year follow up, rate of major adverse coronary events was reduced by approximately 30% by routinely measuring FFR. FAME 2 study randomized 1220 patients with stable coronaryarterydisease and angiographically significant stenoses in whom at least one stenosis had FFR 0.8 Cut off FFR was 0.8
Methods:We used clinical and proteomics data of stroke patients aged 18 years lodged within a prospective plasma repository from 2010 to 2014. We collected blood from each patient at hospital admission before administering any therapeutic intervention. SomaScan quantified 7307 protein targets including 6373 unique proteins.
For females with documented coronaryarterydisease, however, we must tread more carefully. Females in this category require a very nuanced consideration around the risks and benefits of cardiovascular disease risk and also the benefits that come with HRT. Gender differences in coronary heart disease.
Recent research has shown that cardiovascular disease is higher in persons living with HIV compared with individuals without HIV, with an estimated 4-fold higher rate of sudden cardiac death compared with the general population. million lives so far. Abd-Elmoniem, Ph.D., staff scientist in NIDDK’s Biomedical and Metabolic Imaging Branch.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content